277 related articles for article (PubMed ID: 20461438)
1. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Jun; 19(6):807-13. PubMed ID: 20461438
[TBL] [Abstract][Full Text] [Related]
2. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Hesketh PJ; Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
[TBL] [Abstract][Full Text] [Related]
3. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.
Hesketh PJ; Younger J; Sanz-Altamira P; Hayden M; Bushey J; Trainor B; Krentzin M; Nowd P; Arnaoutakis K; Hesketh AM
Support Care Cancer; 2009 Aug; 17(8):1065-70. PubMed ID: 19066985
[TBL] [Abstract][Full Text] [Related]
4. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
[TBL] [Abstract][Full Text] [Related]
5. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
7. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Rapoport BL
Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.
Hesketh PJ; Aapro M; Street JC; Carides AD
Support Care Cancer; 2010 Sep; 18(9):1171-7. PubMed ID: 19756774
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Yeo W; Lau TK; Li L; Lai KT; Pang E; Cheung M; Chan VT; Wong A; Soo WM; Yeung VT; Tse T; Lam DC; Yeung EW; Ng KP; Tang NL; Tong M; Suen JJ; Mo FK
Breast; 2020 Apr; 50():30-38. PubMed ID: 31978815
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.
Roila F; Ruggeri B; Ballatori E; Del Favero A; Tonato M
J Clin Oncol; 2014 Jan; 32(2):101-6. PubMed ID: 24323030
[TBL] [Abstract][Full Text] [Related]
19. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Wenzell CM; Berger MJ; Blazer MA; Crawford BS; Griffith NL; Wesolowski R; Lustberg MB; Phillips GS; Ramaswamy B; Mrozek E; Flynn JM; Shapiro CL; Layman RM
Support Care Cancer; 2013 Oct; 21(10):2845-51. PubMed ID: 23748485
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]